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a  b  s  t  r  a  c  t
Ivermectin  and  doxycycline  have  been  found  to be independently  effective  in killing  body  lice.  In  this
study,  450  body  lice  were  artiﬁcially  fed  on  a ParaﬁlmTM membrane  with  human  blood  associated  with
antibiotics  (doxycycline,  erythromycin,  rifampicin  and azithromycin)  alone  and  in  combination  with
ivermectin.  Fluorescence  in  situ  hybridisation  and  spectral  deconvolution  were  performed  to evaluate
bacterial  transcriptional  activity  following  antibiotic  intake  by  the  lice.  In the  ﬁrst  series,  a lethal  effect  of
antibiotics  on  lice  was  observed  compared  with  the  control  group  at 18 days  (log-rank  test, P ≤  10−3),  with
a  signiﬁcant  difference  between  groups  in  the  production  of  nits  (P =  0.019,  Kruskal–Wallis  test).  A  high
lethal  effect  of  ivermectin  alone  (50  ng/mL)  was  observed  compared  with  the control  group  (log-rank
test,  P ≤  10−3).  Fluorescence  of  bacteriocytes  in  lice  treated  with  20 g/mL doxycycline  was lower  than
in  untreated  lice  (P <  0.0001,  Kruskal–Wallis  test).  In the second  series  with  antibiotic–ivermectin  com-
binations,  a synergistic  lethal  effect  on treated  lice  (log-rank  test,  P < 10−6)  was  observed  compared  with
the  control  group  at 18 days,  associated  with  a  signiﬁcant  decrease  in the  production  of  nits  (P  ≤  0.001,
Kruskal–Wallis  test).  Additionally,  survival  of  lice  in the  combination  treatment  groups  compared  with
ivermectin  alone  was  signiﬁcant  (log-rank  test,  P = 0.0008).  These  data  demonstrate  that  the  synergistic
effect  of combinations  of antibiotics  and  ivermectin  could  be  used  to  achieve  complete  eradication  of  lice
and  to  avoid  selection  of a resistant  louse  population.
©  2016  Elsevier  B.V.  and  the  International  Society  of  Chemotherapy.  All  rights  reserved.. Introduction
The body louse Pediculus humanus humanus is a strictly human
arasite, living and multiplying in clothing; their infestation is asso-
iated with cold weather and a lack of hygiene [1]. Its prevalence
eﬂects the socioeconomic level of the society [2]. In developed
ountries, infestation is more common among the homeless pop-
lation and varies from 7% to 22% [3]. Body lice are extremely
ontagious and pose a serious public health problem. They are
ectors of the pathogens Rickettsia prowazekii,  Bartonella quintana
nd Borrelia recurrentis,  which are responsible for epidemic typhus,
rench fever and relapsing fever, respectively [1,4], and they may
e considered a plague [5].
∗ Corresponding author. Tel.: +33 4 91 32 43 75; fax: +33 4 91 38 77 72.
E-mail address: didier.raoult@gmail.com (D. Raoult).
ttp://dx.doi.org/10.1016/j.ijantimicag.2016.01.001
924-8579/© 2016 Elsevier B.V. and the International Society of Chemotherapy. All rightsFor decades, several antibiotics have proved to be effective in the
treatment of louse-borne diseases. A single dose of 200 mg  doxycy-
cline can cure patients suffering from R. prowazekii-induced typhus
[6], and 500 mg  of tetracycline or erythromycin is optimal ther-
apy for the treatment of B. recurrentis infections [7]. Azithromycin
has been recommended for the treatment of B. quintana infections
[8]. In addition, rifampicin was shown to be effective against some
intracellular bacteria [9]. These results indicate the potential of
antibiotics for the management of louse-borne diseases. Recently,
we demonstrated the in vitro efﬁcacy of doxycycline at different
doses on body lice and found that doxycycline has a direct effect on
endosymbionts of lice through the mycetome switch [10].
Several strategies for eradication of these parasites have been
used to avoid the spread and/or outbreak of these diseases. How-
ever, some products have already shown their limits. The resistance
of lice to lindane in Europe, Africa and Asia [11] and to DDT  in Korea
and Japan [12,13] has been reported. Pyrethroids have been widely
used, however resistance to these compounds has emerged and
 reserved.
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pread over the last decade. In the head louse, resistance to per-
ethrin was ﬁrst reported in France in 1994 and throughout the
orld thereafter [14]. Ivermectin is a synthetic derivative of the
ntiparasitic class of compounds known as avermectins [15]. Resis-
ance to ivermectin and related drugs is an increasing problem for
arasite control [16]. Previous studies have associated ATP-binding
assette (ABC) transporters with drug resistance in nematodes
17] and arthropods [18]. However, resistance to ivermectin has
lso been documented in insects and mites of plants [19] and in
ematodes [16]. Resistance to ivermectin has been documented in
hipicephalus (Boophilus) microplus ticks in Mexico [20]. The occur-
ence of resistance to macrocyclic lactones has been reported in
ther arthropods [21]. Used in scabies, clinical and in vitro resis-
ance have been documented in two patients who received 30 and
8 doses of ivermectin, respectively [22].
Today, post-therapeutic re-infestation of the vector of diseases
lice) is common and still remains a real challenge, thus there
s a need to develop new therapeutic strategies to avoid these
e-infestations. It was observed that avermectin B1a could act syn-
rgistically with the antibiotic meticillin to kill meticillin-resistant
taphylococcus aureus (MRSA), rendering the bacteria once again
ulnerable to meticillin [23]. The hypothesis that the bacterial
ymbiont Candidatus Riesia pediculicola is a possible target for
he development of louse control strategies [24] was  recently
onﬁrmed in our previous work [10]. In this study we  aimed to
emonstrate the in vitro combination of ivermectin with several
ntibiotics as a synergistic association to achieve complete eradi-
ation of lice and to avoid the selection of a resistant population of
ice.
. Materials and methods
.1. Louse feeding system in vitro
A long-established inbred line of the human body louse (P.
. corporis, Orlando strain), which had been bred on rabbits in
 laboratory pet shop by our URMITE team in Marseille, France,
as used as a model in the experiments in this study [25]. A
emotekTM feeding system (Discovery Workshops, Accrington, UK)
ith a ParaﬁlmTM membrane (Chicago, IL), a PS5A/220 Power Unit
HemotekTM 5W1  System; Discovery Workshops) and six heating
nits was used (Fig. 1). A square of synthetic feeding membrane
easuring ca. 3 cm × 3 cm was stretched around the aperture of
he blood meal reservoir and was secured with an O-ring (Fig. 1a).
he feeding area was sufﬁcient for 100 lice (Fig. 1b). The blood
eal reservoir was removable for easy cleaning and autoclaving
f necessary. The system does not use animal hosts and enables
odiﬁcation of the meal by introduction of chemicals or infectious
gents and accurate adjustment of the temperature through heat-
ng units (Fig. 1c) connected directly to the power unit (Fig. 1d).
ice were fed every day at 37 ◦C for 1 h (Fig. 1e).
.2. Preparation of blood meal supplemented with antibiotics and
vermectin
Human blood group A rhesus positive (A+) [code 74883 from
he French Blood Service (EFS)] was used. Ethical approval for the
se of human blood in vitro was obtained from the Laboratory
esearch Ethics Board of Molecular Hematology, EFS. Blood was
istributed into 5 mL  tubes and was kept at −20 ◦C before use. The
lood was warmed in a water bath at 37 ◦C for 30 min  before use.
rugs used were in injectable and oral form as follows: doxycycline
0 mg/mL  (Vibraveineuse® batch A262408; Laboratoires SERB,
aris, France); erythromycin 1 g (Erythrocine® batch 24370TB22;
mdipharm Ltd., Dublin, Ireland); rifampicin 600 mg  (Rifadine®timicrobial Agents 47 (2016) 217–223
batch A3468; Sanoﬁ-Aventis, Paris, France); azithromycin 600 mg
(Azadose® batch 490004; Pﬁzer Holding, Paris, France); and iver-
mectin 10 mg/mL  (Ivomec® batch BM295/12; Merial, Lyon, France).
For each group of lice, 15 L of uncombined antibiotic diluted
at concentrations (doxycycline 20 g/mL, erythromycin 4 g/mL,
rifampicin 10 g/mL and azithromycin 8 g/mL) previously estab-
lished for the ﬁrst series of experiments was  added to a volume of
1.485 mL of haemolysed blood. In the second series for each group
of lice, 15 L of antibiotic (doxycycline 20 g/mL, erythromycin
4 g/mL, rifampicin 10 g/mL and azithromycin 8 g/mL) plus
15 L of ivermectin diluted at a concentration (50 ng/mL) previ-
ously established was added to a volume of 1.470 mL of haemolysed
blood. The ﬁnal volume of 1.5 mL  obtained for each concentration
was introduced into different reservoirs. The reservoir was then
attached to the feeder by screwing it onto a nylon stud on the heat
transfer plate at the bottom of the feeder.
2.3. Monitoring of lice and nits
In total, 450 adult lice [excluding 10 lice sacriﬁced as live con-
trols in ﬂuorescence in situ hybridisation (FISH)] were used in the
experiments. Lice were divided into groups of 45, were placed on
a piece of black cloth and were kept in jars in an oven at 29 ◦C and
90% humidity as breeding lice. The ﬁrst series of experiments was
performed without combination of drugs and the second was based
on the antibiotic–ivermectin combinations. A group of lice treated
with ivermectin alone was  monitored in parallel with the com-
bination series. The control group was fed exclusively with blood
without drugs throughout the experiments. Lice were placed on the
membrane daily for 1 h of blood meal feeding. Every day, survival
was determined by assessing the number of nits in each group and
was recorded on a data collection sheet before the next meal (Sup-
plementary Tables S1 and S2). All of the experiments were repeated
three times for reproducibility.
Supplementary Tables S1 and S2 related to this article can
be found, in the online version, at http://dx.doi.org/10.1016/j.
ijantimicag.2016.01.001.
2.4. Fluorescence in situ hybridisation (FISH)
For the FISH technique, the aim was to highlight the effect of
the antibiotic (especially doxycycline) on the louse endosymbiont
as previously demonstrated [10]. Thus, ten specimens were tested
in each untreated group (living controls and dead controls) and
in the doxycycline 20 g/mL group (Table 1). Following ﬁxation,
samples were decolourised in 6% H2O2 in ethanol for 2 h and were
then placed in hybridisation buffer [20 mM Tris–HCl (pH 8.0), 0.9 M
NaCl, 0.01% sodium dodecyl sulphate and 30% formamide] con-
taining 10 pmol of ﬂuorescent probe/mL based on the Candidatus
Riesia pediculicola 16S rRNA sequence: Cy3-Lice1255R (5′-Cy3-
TTGGCTCGCTCTTACGAGT-3′) [10].
2.5. Light and confocal microscopy
The spectral deconvolution technique was used to differentiate
autoﬂuorescence caused by chitin from clean ﬂuorescence. First,
the louse was marked and mounted between slide and cover slip
and imaging was  performed as follows using a Leica SP5 AOBS® con-
focal resonant scanner (Leica Microsystems, Mannheim, Germany)
in Lambda mode. The sample was scanned on a total band of 160 nm
and a slit width of 5 nm taking care to never saturate the signal.
Fluorescence measurement was  deﬁned as the extraction of curves
(one for ﬂuorescence and one for autoﬂuorescence). After creation
of the reference curves, all acquisitions were made with exactly the
same settings for gain, offset, laser power and objective. For each
acquisition, 32 pictures were collected. Once the references were
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Fig. 1. The HemotekTM 5W1  membrane feeding system for lice: (a) the device’s meal rese
the  device; (c) the heating units; (d) the PS5 power unit; and (e) blood meal feeding of lic
Table 1
Measurement of ﬂuorescence intensity in three populations of lice.
Group Day Total area Surface marked Intensity ratio
Doxycycline
20 g/mL
1 16,217 1205 7.4
2  4808 325 6.7
3  29,970 1385 5.9
4  32,994 2179 6.6
5  19,730 1190 6
6  29,211 1537 5.2
7  51,047 2468 4.8
8  20,479 1216 4.6
9  37,185 1231 3.3
10 16,231 395 2.4
Dead
con-
trols
1  8977 1462 16.2
2  9523 1275 13.3
3  9488 1358 14.3
4  13,279 1755 13.2
5  12,391 1518 12.2
6  9873 1280 12.9
7  9173 1051 11.4
8  10,506 1163 11
9  9923 986 9.9
10 12,675 1269 10
Living
con-
trols
1  12,861 1943 15.1
2  12,496 1605 12.8
3  11,058 1467 13.2
4  7558 1249 16.5
5  10,913 1134 10.3
6  7945 1156 14.5
7  8962 1580 17.6
8  12,381 1397 11.2
9  9914 1290 13
10 13,091 1898 14.4rvoir (a1, blood meal reservoir; a2, plastic ring; and a3, ParaﬁlmTM); (b) assembling
e on artiﬁcial membrane.
determined and assigned, the samples were spectrally deconvolved
and the signals were separated by assigning them a distinct colour.
2.6. Calculation of intensity ratios
MetaMorph v.4.6 (Molecular Devices, Sunnyvale, CA) and a gen-
erated Excel table (Microsoft Corp., Redmond, WA)  were used to
calculate the intensity ratios.
2.7. Statistical analysis
Data were stored in Excel. Analyses were performed with R
software v.3.1.1 (R Foundation for Statistical Computing, Vienna,
Austria). Kaplan–Meier estimations and log-rank test were used
for survival analysis. Analysis of Kruskal–Wallis non-parametric
test was used for mean comparisons. Bonferroni correction was
applied for subgroup tests. The statistical tests represent bilateral
situations, and P-values of ≤0.05 were considered signiﬁcant.
3. Results
Feeding lice on artiﬁcial membranes enabled them to be treated
with antibiotics and ivermectin. The blood feeding rate was  >95%
in all treatment arms (Fig. 1e).
3.1. Effect of antibiotics on the survival of lice and on nit
production
To determine the effect of antibiotics, in the ﬁrst series of
experiments each group of lice treated with either doxycy-
cline 20 g/mL, erythromycin 4 g/mL, rifampicin 10 g/mL or
azithromycin 8 g/mL as well as the controls were followed until
the end. Survival of lice in the control group was  signiﬁcantly dif-
ferent from survival in the treated groups (log-rank test, P ≤ 10−3)
220 A.K. Sangaré et al. / International Journal of Antimicrobial Agents 47 (2016) 217–223
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ﬁig. 2. Evolution trends in the antibiotic treatment groups. (a) Kaplan–Meier curves
b)  Mean (±95% CI) number of eggs laid per day in the doxycycline-, erythromyc
nterval; Doxy, doxycycline; Ery, erythromycin; Rifam, rifampicin; Azith/Azithro, az
Fig. 2a). Moreover, a decrease in the production of nits was
bserved in the treated groups compared with the control group
Fig. 2b), with mean [95% conﬁdence interval (CI)] number of eggs
aid per day of 7.5 (2.5–12.5), 9.8 (4.3–15.3), 10 (4.6–15.6), 7.7
2.2–13.2) and 17.8 (13.3–22.3) in the doxycycline-, erythromycin-
 rifampicin- and azithromycin-treated groups and the control
roup, respectively. The difference in mean nit production was
igniﬁcant between the groups (P = 0.019, Kruskal–Wallis test).
.2. Direct effect of doxycycline on the lice mycetome analysed
hrough FISH
To show that doxycycline affects the louse’s endosymbionts, we
ocused on a new analysis based on spectral deconvolution to cal-
ulate the ratios between the two signals (Table 1). By using the
unction extraction curve computation of reply in emission and
ositioning the reference areas on distinctive signals, two  curves
ere extracted: one for speciﬁc ﬂuorescence of the bacterium
nd one for autoﬂuorescence of the louse. Thus, the results show
hat bacterial ﬂuorescence in the group treated with doxycycline
0 g/mL (Fig. 3a) was lower than in the untreated groups (living
nd dead controls) (Fig. 3b and c) (P < 0.0001, Kruskal–Wallis test).
.3. Effect of ivermectin alone on the survival of lice and
roduction of nits
To determine the antiparasitic action of ivermectin alone, lice
reated with 50 ng/mL ivermectin were followed until the end of
he experiment. A high mortality rate was found compared with
he control group (log-rank test, P ≤ 10−3) at 18 days (Fig. 4a). A
igniﬁcant difference between groups was observed in mean nit
roduction (P = 0.001, Kruskal–Wallis test), with mean (95% CI)
umber of eggs laid per day of 5.2 (0.6–9) and 17.8 (13.3–22.3),
espectively (Fig. 4b).
.4. Synergistic effect of antibiotics and ivermectin on survival of
ice and production of nitsTo determine the antiparasitic synergistic action of ivermectin
ombined with antibiotics, in a second series of experiments
ve groups of lice were tested for their survival kinetics. Inrating survival of lice treated with antibiotics in comparison with the control group.
fampicin- and azithromycin-treated groups and the control group. CI, conﬁdence
ycin.
the combination groups (doxycycline 20 g/mL + ivermectin
50 ng/mL, erythromycin 4 g/mL + ivermectin 50 ng/mL,
rifampicin 10 g/mL + ivermectin 50 ng/mL or azithromycin
8 g/mL + ivermectin 50 ng/mL), lice were more rapidly killed
compared with the control group, exhibiting potent synergistic
action (log-rank test, P < 10−6) (Fig. 5a). Moreover, a signiﬁcant
decrease in the production of nits was  observed in the combination
groups compared with the control group (Fig. 5b), with mean (95%
CI) eggs per day of 2.4 (−0.9 to 5.8), 4.4 (−0.1 to 9.0), 4.0 (−0.6
to 8.6), 3.6 (−0.5 to 7.7) and 17.8 (13.3–22.3), respectively. Thus,
the difference in mean production of nits between groups was
signiﬁcant (P ≤ 0.001, Kruskal–Wallis test). Moreover, overall sur-
vival of lice in the combination treatment groups compared with
ivermectin alone was also signiﬁcant (log-rank test, P = 0.0008)
(Fig. 6a). Therefore, the difference was  signiﬁcant when comparing
the combination groups with the ivermectin and control groups
(Fig. 6b).
4. Discussion
For decades, complete eradication of human lice has remained
challenging. In the ﬁrst in vitro series of experiments, the lethal
effect of the antibiotics doxycycline, erythromycin, rifampicin and
azithromycin on lice was observed compared with the control
group at 18 days, associated with a decrease in the production
of nits. Of the four antibiotics tested, doxycycline appeared to be
more effective than rifampicin, azithromycin and erythromycin,
with a variable survival time according to treatment group (Fig. 2a;
Supplementary Table S1). Recently, the in vitro efﬁcacy of doxy-
cycline at different doses on body lice was  demonstrated [10]. In
light of these results, we can suggest that the use of antibiotics
(doxycycline, rifampicin, azithromycin and erythromycin) alone or
in combination could be an efﬁcient way to develop new drugs and
to overcome drug resistance in lice.
Several decades ago it was demonstrated that body lice depend
on obligate endosymbionts to supplement their nutritionally-
deﬁcient blood diet [26]. However, they maintain organs called
mycetomes that house the primary endosymbiont [27]. Thus,
through FISH analysis we were able to demonstrate that damage to
the symbiont bacteria caused the death of their host as conﬁrmed
A.K. Sangaré et al. / International Journal of Antimicrobial Agents 47 (2016) 217–223 221
Fig. 3. Images of lice by confocal microscopy through the technique of spectral deconvolution: (a) louse treated with doxycycline 20 g/mL taken at Day 10 showing lower
bacterial ﬂuorescence; (b) living control showing higher bacterial ﬂuorescence; (c) dead control taken at Day 10 showing lower bacterial ﬂuorescence; and (d) louse tested
with  negative probe showing no bacterial ﬂuorescence.
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ontrol group. (b) Mean (±95% CI) number of eggs laid per day in the ivermectin (Iv
y a decrease in bacterial ﬂuorescence (Fig. 3a). These results cor-
oborate our previous work showing that doxycycline may  affect
he endosymbionts of lice through the mycetome switch, thus caus-
ng death of the louse [10].
Despite the introduction of some products such as organophos-
hates, pyrethrins and pyrethroids, insecticide resistance remains
n increasing problem in many insect vectors of disease [14], espe-
ially among lice. Expression levels of ABC transporters have also
een associated with drug resistance in arthropods and nema-
odes. Overexpression of these ABC transporters is associated with
vermectin resistance in Haemonchus contortus [16], Caenorhab-
itis elegans [17], P. h. humanus [28], Sarcoptes scabiei [29] andes illustrating survival of lice treated with ivermectin (Iv) in comparison with the
eated group and the control group. CI, conﬁdence interval.
R. microplus [18]. In a cohort of homeless subjects in Marseilles
(France), a prevalence of body lice of 85% was  observed [30]. This
infestation was reduced temporarily to 19% with three doses of oral
ivermectin administered at 7-day intervals. However, treatment
failure or early recrudescence is common following ivermectin
alone, and multiple doses are usually required to achieve a cure
[31]. Moreover, in their randomised trial Chosidow et al. suggest
that ivermectin could be an alternative treatment [32], but its tran-
sient effect was also demonstrated in some studies [3]. The ﬁndings
of the current study show the transient effect of ivermectin alone
on lice with a monitoring time of 10 days, associated with a slow
decrease in the production of nits (Fig. 4; Supplementary Table S2).
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Fig. 5. Evolution trends in the antibiotic–ivermectin combination treatment groups. (a) Kaplan–Meier curves illustrating survival of lice treated with the antibiotic–ivermectin
combinations in comparison with the control group. (b) Mean (±95% CI) number of eggs laid per day in the combination treatment groups and the control group. CI, conﬁdence
interval; Iv/Iver, ivermectin; Doxy, doxycycline; Ery, erythromycin; Rifam, rifampicin; Azith/Azithro, azithromycin.
Fig. 6. Evolution trends in the antibiotic–ivermectin combination treatment groups and the ivermectin alone treatment group. (a) Kaplan–Meier curves illustrating survival
of  lice treated with antibiotic–ivermectin combinations and with ivermectin alone. (b) Kaplan–Meier curves illustrating the comparison of overall survival of lice in the
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hus, in light of these various therapeutic failures, we  may  con-
lude that ivermectin could be useful with other drugs of different
lasses especially antibiotics, in the control of body lice infestation.
The efﬁcacy of drug combination with ivermectin has been
emonstrated in nematodes [33] and ectoparasites [34]. For iver-
ectin, it was suggested that head lice may  be more susceptible
han body lice; this could be justiﬁed by the model of Mumcuoglu
t al., who observed high mortality of nymphs and female body lice
ed on rabbits treated with 200 g/kg ivermectin for 3 days, fol-
owed by a sharp decline reaching the level of the controls on Day 6
35]. In light of the various therapeutic failures described in lice, we
ecided test antibiotic combinations with ivermectin. In the sec-
nd series of in vitro experiments, we were able to demonstrate
he antiparasitic synergistic activity of a combination of several
rugs. The monitoring time ranged from 5 days to 7 days in theup. Iv/Iverm, ivermectin; Doxy, doxycycline; Ery, erythromycin; Rifam, rifampicin;
combination group, whilst that of ivermectin alone was  10 days
(Supplementary Table S2). Interestingly, the difference in overall
survival of lice in the combination treatment groups compared with
ivermectin alone was also signiﬁcant. Thus, these results highlight
the efﬁcacy of drug combinations compared with ivermectin alone.
In the literature, compounds including antibiotics have been shown
to increase intracellular concentrations of macrocyclic lactones
[36]. In addition, it was shown that drug combinations including
ivermectin provide antiﬁlarial activity with ancillary beneﬁts on
intestinal helminths and ectoparasites such as chiggers and lice
[34]. When doxycycline was  combined with macrocyclic lactones
in adult worms, ivermectin efﬁcacy was  ca. 80% compared with
9% when treatment was performed with doxycycline alone [37].
Hoerauf et al. recommend concurrent administration of ivermectin
with doxycycline in the treatment of Onchocerca worms carrying
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olbachia endobacteria [38], and later Coulibaly et al. found a
igniﬁcant reduction of circulating antigen levels of Wuchereria
ancrofti in groups treated with a combination of doxycycline plus
vermectin for 12 months [39]. The effect of this combination has
lso been conﬁrmed in dogs naturally infected with Diroﬁlaria
mmitis [40]. Thus, the current results are in agreement with the
iterature, especially that of Guo et al., which identiﬁes for the
rst time that avermectin (macrocyclic lactone derivative including
vermectin) could act synergistically with meticillin (an antibi-
tic) to kill bacteria (MRSA) [23]. In addition, the current study
emonstrates the ﬁrst synergistic association of these drugs in vitro
gainst body lice. We  believe that the synergistic effect of com-
inations of antibiotics plus ivermectin could be used to achieve
omplete eradication of lice and to avoid the selection of a resistant
opulation of lice.
. Conclusion
The present study demonstrates a synergistic effect of antibi-
tics combined with ivermectin to even more effectively control
ice. Thus, it would be interesting to develop this model in vivo in
he control of lice infestation in humans.
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